These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 19236120

  • 41. 'Extreme duplication' in the US FDA Adverse Events Reporting System database.
    Hauben M, Reich L, DeMicco J, Kim K.
    Drug Saf; 2007; 30(6):551-4. PubMed ID: 17536881
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Pediatric Drug Safety Surveillance in FDA-AERS: A Description of Adverse Events from GRiP Project.
    de Bie S, Ferrajolo C, Straus SM, Verhamme KM, Bonhoeffer J, Wong IC, Sturkenboom MC, GRiP network.
    PLoS One; 2015; 10(6):e0130399. PubMed ID: 26090678
    [Abstract] [Full Text] [Related]

  • 48. An Algorithm to Identify Generic Drugs in the FDA Adverse Event Reporting System.
    Iyer G, Marimuthu SP, Segal JB, Singh S.
    Drug Saf; 2017 Sep; 40(9):799-808. PubMed ID: 28593504
    [Abstract] [Full Text] [Related]

  • 49. Quality assessment of spontaneous triggered adverse event reports received by the Food and Drug Administration.
    Brajovic S, Piazza-Hepp T, Swartz L, Dal Pan G.
    Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):565-70; discussion 571-2. PubMed ID: 22359404
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithms.
    Hauben M, Reich L, Chung S.
    Eur J Clin Pharmacol; 2004 Dec; 60(10):747-50. PubMed ID: 15619136
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
    Hoffman KB, Dimbil M, Tatonetti NP, Kyle RF.
    Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS).
    Rahman MM, Alatawi Y, Cheng N, Qian J, Peissig PL, Berg RL, Page DC, Hansen RA.
    Clin Drug Investig; 2017 Dec; 37(12):1143-1152. PubMed ID: 28933038
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Data mining in pharmacovigilance--detecting the unexpected: the role of index of suspicion of the reporter.
    Sundström A, Hallberg P.
    Drug Saf; 2009 Dec; 32(5):419-27. PubMed ID: 19419236
    [Abstract] [Full Text] [Related]

  • 59. Natural Health Product-Drug Interaction Causality Assessment in Pediatric Adverse Event Reports Associated with Attention-Deficit/Hyperactivity Disorder Medication.
    Mazhar H, Foster BC, Necyk C, Gardiner PM, Harris CS, Robaey P.
    J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):38-47. PubMed ID: 31670573
    [Abstract] [Full Text] [Related]

  • 60. Brand vs generic adverse event reporting patterns: An authorized generic-controlled evaluation of cardiovascular medications.
    Alatawi Y, Rahman MM, Cheng N, Qian J, Peissig PL, Berg RL, Page CD, Hansen RA.
    J Clin Pharm Ther; 2018 Jun; 43(3):327-335. PubMed ID: 29092097
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.